Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486293 | 0.94 | NPC1 (0.46) | RAB9ANPC1MEN1KMT2ALTA4H | |
| SCHEMBL19486295 | 0.85 | PRSS1 (0.36) | RAB9ANPC1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL11725735 | 0.84 | PRSS1 (0.49) | RAB9ANPC1MEN1KMT2AMMP1 | |
| SCHEMBL19486508 | 0.83 | GAA (0.51) | RAB9ANPC1MAPTGAATP53 | |
| SCHEMBL19486143 | 0.81 | RAB9A (0.49) | RAB9ANPC1MEN1KMT2AMMP1 | |
| SCHEMBL19486298 | 0.80 | RAB9A (0.48) | RAB9ANPC1MEN1KMT2AMMP1 | |
| SCHEMBL19486225 | 0.79 | ALDH1A1 (0.55) | RAB9ANPC1MEN1KMT2AMMP1 | |
| SCHEMBL19486507 | 0.77 | L3MBTL1 (0.48) | RAB9ANPC1MAPTSMN1; SMN2GAA | |
| SCHEMBL19486297 | 0.76 | L3MBTL1 (0.47) | RAB9ANPC1MAPTSMN1; SMN2GAA | |
| SCHEMBL7213335 | 0.76 | TP53 (0.50) | RAB9ANPC1MAPTGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298057-A1 | DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS | ARIXA PHARMACEUTICALS, INC. | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298057-A1 | DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS | DDOST, LBR, STS | RAB9A 2118/4885NPC1 2499/4885MEN1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.